Abstract |
The development of pulmonary side effects, especially pulmonary fibrosis, during treatment with bleomycin is well documented in adult oncology patients, but not in children. A report of fatal pulmonary fibrosis which developed after exposure to oxygen while under anesthesia in a 3-year-old boy treated with bleomycin exemplifies the problem. The prevention of long-term complications associated with bleomycin is especially important in children, since a child cured of a malignant neoplasm may enjoy many years of productive life. Given the present limitations, guidelines for management of pediatric patients given bleomycin include: discontinuation of bleomycin therapy with the onset of symptoms; serial pulmonary function testing during the course of treatment; and early treatment with high-dose corticosteroids ( prednisone 2 mg/kg/day) if symptoms occur.
|
Authors | H Eigen, D Wyszomierski |
Journal | The American journal of pediatric hematology/oncology
(Am J Pediatr Hematol Oncol)
Vol. 7
Issue 1
Pg. 71-8
( 1985)
ISSN: 0192-8562 [Print] United States |
PMID | 2412460
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
|
Topics |
- Bleomycin
(adverse effects)
- Castration
- Child, Preschool
- Humans
- Lung
(drug effects, pathology)
- Male
- Teratoma
(drug therapy, surgery)
- Testicular Neoplasms
(drug therapy, surgery)
|